TABLE OF CONTENTS

PROGRAM SUMMARY ......................................................................................................................................................... 3
APPLICATION DEADLINE .................................................................................................................................................. 3
APPLICANT ELIGIBILITY CRITERIA .................................................................................................................................. 3
RESEARCH PROJECT CRITERIA .......................................................................................................................................... 4
EVALUATION OF APPLICATIONS ..................................................................................................................................... 5
TOBACCO INDUSTRY FUNDING AND CONFLICTS OF INTEREST STATEMENT ......................................................... 5
APPLICATION PROCEDURES ......................................................................................................................................... 7
GETTING STARTED IN proposalCENTRAL .................................................................................................................. 8
APPLICATION FORMAT .................................................................................................................................................. 8
SUBMITTING COMPLETE APPLICATION ....................................................................................................................... 15
CHANGES TO YOUR APPLICATION ............................................................................................................................ 16
INQUIRIES ....................................................................................................................................................................... 17
TABLE 1: INSTITUTIONS THAT HOLD A MATERIALS TRANSFER AGREEMENT WITH NOVOCURE ..................... 18
MORE ABOUT THE PARTNERS ....................................................................................................................................... 19
PROGRAM GUIDELINES

PROGRAM SUMMARY
The AACR-Novocure Tumor Treating Fields Research Grants represent a joint effort to promote and support independent investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells). These grants are intended to provide a deeper understanding of the mechanisms of action of this novel anti-cancer treatment modality and to accelerate the development of new treatment strategies to advance therapeutic options for cancer. The research proposed for funding should be basic or translational in nature, promoting the transition of in vitro work into in vivo systems. Proposals focused on 1) translational approaches, promoting the transition of in vitro work into in vivo systems, 2) combination therapies involving TTFields, or 3) bringing treatments involving TTFields to the clinic, are strongly encouraged.

Applications are invited from researchers affiliated with institutions* that currently hold a Materials Transfer Agreement (MTA) with Novocure for use of its devices (*Please see Table 1 for a list of institutions on page 18).

In addition, applications are invited from researchers that have not yet entered into a Materials Transfer Agreement (MTA) with Novocure. If selected for funding, Novocure will work with the institution to execute a MTA to provide the necessary devices to complete the research. For additional details, please see the Materials Transfer Agreement and Terms and Conditions.

Each grant provides $250,000 over two years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators**, postdoctoral or clinical research fellows, graduate students and/or research assistants; research/laboratory supplies; equipment; travel; publication charges for manuscripts that pertain directly to the funded project; other research expenses; and indirect costs. (**Note that inter-laboratory collaboration is encouraged.)

APPLICATION DEADLINE
December 11, 2019, at 1:00 p.m. U.S. Eastern Time

NOTIFICATION OF AWARD
February 2020

ANNUAL GRANTS RECEPTION AND DINNER AT AACR ANNUAL MEETING 2020
April 28, 2020 – Grant recipients must attend the Grants Reception and Dinner to formally accept the grant. Grant funds may be used to support the grantee’s registration and attendance at this Annual Meeting.

START OF GRANT TERM
July 1, 2020

APPLICANT ELIGIBILITY CRITERIA
Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.
Applications will be accepted from independent investigators who are affiliated with an institution* that currently holds an active MTA with Novocure for use of its devices, or an institution that will enter into a MTA with Novocure. (*Please see Table 1 for a list of institutions on page 18.)

There are no citizenship requirements; however, by submitting an application for this grant, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which they applied.

Applicants should be AACR members. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active membership, and be members in good standing, by the grant application deadline. Nonmembers can apply for membership using the Official Application for Membership submitted to the AACR with the required documents or apply online. Suspended Members can renew their membership through their myAACR account. Lapsed members should contact the Membership Department at membership@aacr.org for assistance and with any questions.

Investigators may submit only one application for the AACR-Novocure Tumor Treating Fields Research Grants but may concurrently apply for other AACR grants. However, applicants are expected to accept the first grant they are awarded. Individuals may accept and hold only one AACR grant at a time.

Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible. Employees or subcontractors of a U.S. government entity or for-profit private industry may serve as Collaborators, but no grant funds may be directed towards these individuals.

Any individual who currently holds an active AACR grant may not apply. Past AACR grantees may apply if they complied with all progress and financial report requirements.

Postdoctoral or clinical research fellows or the equivalent who are working under the auspices of a scientific mentor are not eligible to apply. Qualified fellows are invited to apply for an AACR Fellowship.

Members of the Scientific Review Committee are not eligible to apply for a AACR-Novocure Tumor Treating Fields Research Grant.

All applicants with questions about eligibility should contact AACR’s Scientific Review and Grants Administration Department (the AACR’s SRGA) at grants@aacr.org before submitting an application.

RESEARCH PROJECT CRITERIA

Research projects should examine the use of TTFields as a therapeutic modality. The research proposed for funding should be basic or translational in nature, promoting the transition of in vitro work into in vivo systems. Proposals focused on 1) translational approaches, promoting the transition of in vitro work into in vivo systems, 2) combination therapies involving TTFields, or 3) bringing treatments involving TTFields to the clinic are strongly encouraged.

Research proposals must incorporate use of the Inovitro® system into the experimental design. For grant recipients who are affiliated with institutions that do not currently hold a Materials Transfer Agreement (MTA) with Novocure for use of its devices, Novocure will provide this system to complete
the research. For additional details, please see the MTA and Terms and Conditions. If selected for funding, Novocure will work with the institution to execute a MTA.

EVALUATION OF APPLICATIONS
Applications will be peer-reviewed by a Scientific Review Committee comprised of researchers and physician-scientists who are well-respected for their own accomplishments in cancer research and viewed as leaders in the field. The President of AACR will appoint the members of the Scientific Review Committee.

The Committee will consider the following criteria when reviewing applications and determining funding decisions:

- **Investigator.** Is the applicant well suited to the project? Does the applicant have appropriate experience and training to successfully complete the proposed project? Has the applicant achieved, or have the potential of achieving, a track record, of accomplishments to advance the field?

- **Scientific Focus and Originality.** Is the research focused on TTFields? Is this research project unique and non-duplicative of other projects currently in the field?

- **Innovation and Significance.** Does the research have the potential to provide novel insights for the treatment of cancer using TTFields? Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved?

- **Approach.** Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? Is the budget fully justified and reasonable in relation to the proposed project?

- **Environment.** Is sufficient evidence provided of institutional commitment to the applicant? What institutional support, equipment, and resources are available to the applicant and are they adequate to successfully complete the proposed project?

TOBACCO INDUSTRY FUNDING AND CONFLICTS OF INTEREST STATEMENT
Scientific investigators or health professionals who are funded by the tobacco industry for any research project are not eligible for any AACR grant. Grantees who accept funding from the tobacco industry for any research project during the term of an AACR grant must inform the AACR of such funding, whereupon the AACR grant will immediately be terminated.

Tobacco industry funding is defined for purposes of AACR grant applicants and recipients as money provided or used for all or any of the costs of any research project, including personnel, consumables, equipment, buildings, travel, meetings and conferences, and operating costs for laboratories and offices. It is not defined as money provided or used for meetings or conferences that don’t relate to any particular research projects.

Tobacco industry funding includes: funds from a company that is engaged in or has affiliates engaged in the manufacture of tobacco produced for human use; funds in the name of a tobacco brand, whether or not the brand name is used solely for tobacco products; funds from a body set up by the tobacco industry or by one or more companies engaged in the manufacture of tobacco products. The following do not constitute tobacco industry funding for the purposes of this policy:
• Legacies from tobacco industry investments (unless the names of a tobacco company or cigarette brand are associated with them)
• Funding from a trust or foundation established with assets related to the tobacco industry but no longer having any connection with the tobacco industry even though it may bear a name that (for historical reasons) is associated with the tobacco industry
APPLICATION INSTRUCTIONS

APPLICATION PROCEDURES
The AACR requires applicants to submit an online application by **1:00 p.m. U.S. Eastern Time on Wednesday, December 11, 2019**, using the proposalCENTRAL website at [https://proposalcentral.com](https://proposalcentral.com).

In order to submit a complete application, applicants need to enter information directly into the online application platform as well as upload a number of documents. The following instructions provide details about information that needs to be entered and the materials that need to be uploaded. The section numbering corresponds with the section number of the Application Instructions and the online proposalCENTRAL application.

### Information to be Entered Directly into proposalCENTRAL

<table>
<thead>
<tr>
<th>Project Title and Acknowledgement of Terms and Conditions</th>
<th>1. Title Page</th>
<th>1) Title Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Information</td>
<td>4. Applicant</td>
<td>4) Applicant</td>
</tr>
<tr>
<td>Institution and Contact Information</td>
<td>5. Institution &amp; Contacts</td>
<td>5) Institution &amp; Contacts</td>
</tr>
<tr>
<td>Collaborator Information (if applicable)</td>
<td>6. Collaborators</td>
<td>6) Collaborators</td>
</tr>
<tr>
<td>Scientific Abstract</td>
<td>7. Scientific Abstract</td>
<td>7) Scientific Abstract</td>
</tr>
<tr>
<td>Budget</td>
<td>8. Budget</td>
<td>8) Budget</td>
</tr>
<tr>
<td>Organizational Assurances</td>
<td>9. Organizational Assurances</td>
<td>9) Organizational Assurances</td>
</tr>
</tbody>
</table>

### Templates

<table>
<thead>
<tr>
<th>Research Project Proposal Template</th>
<th>10.A. Application Documents</th>
<th>10) Application Documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secured Other Support Template</td>
<td>10.B. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Pending Other Support Template</td>
<td>10.C. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Budget Justification Template</td>
<td>10.D. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Project Milestones Template</td>
<td>10.E. Application Documents</td>
<td>10) Application Documents</td>
</tr>
</tbody>
</table>

### Additional Materials

<table>
<thead>
<tr>
<th>Applicant’s Biographical Sketch</th>
<th>10.F. Application Documents</th>
<th>10) Application Documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Institutional Commitment</td>
<td>10.G. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Collaborator Biographical Sketch(es) (if applicable)</td>
<td>10.H. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Letter(s) of Collaboration (if applicable)</td>
<td>10.I. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Supporting Documentation (if applicable)</td>
<td>10.J. Application Documents</td>
<td>10) Application Documents</td>
</tr>
<tr>
<td>Appendices (if applicable)</td>
<td>10.K. Application Documents</td>
<td>10) Application Documents</td>
</tr>
</tbody>
</table>

### Required Signatures

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Signature Page</td>
<td>10.M. Application Documents</td>
<td>13) Signature Page(s)</td>
</tr>
</tbody>
</table>
GETTING STARTED IN proposalCENTRAL

If you are a new user of proposalCENTRAL, click the orange “CREATE ONE NOW!” button and complete the registration process. After logging in, complete your Professional Profile (green tab) before starting an application.

If you are already registered with proposalCENTRAL, access the site and log in with your Username and Password. If you have forgotten your login information, click on the “Forgot Your Username/Password?” link.

To start an application, select the “Grant Opportunities” tab (gray tab). A list of grant opportunities will be displayed. The list of applications can be filtered for just this organization by clicking “Filter by Grant Maker” at the top and selecting “American Association for Cancer Research” in the drop down menu. Find the “AACR-Novocure Tumor Treating Fields Research Grants” and click the blue “Apply Now” button in the “Apply” column.

If you have any difficulties registering, logging in, or creating your application, contact proposalCENTRAL Customer Support at 800-875-2562 (Toll-free U.S. and Canada), +1-703-964-5840 (Direct Dial International), or by email at pcsupport@altum.com. See the proposalCENTRAL FAQ section, for additional information.

APPLICATION FORMAT

The following information is required to submit a complete application. Numbers correspond to the application sections found on the left side of the proposalCENTRAL website.

1. TITLE PAGE. Enter the title of the research project. The title is limited to no more than 75 characters (including spaces). Do not use abbreviations. **A project title must be entered and saved before additional sections may be accessed.**

   Terms and Conditions of the Grant. In order to ensure that the applicant is informed of the terms and conditions of the grant should they be selected as a recipient, applicant must acknowledge that they have read the terms and conditions and have shared them with their institution by typing in their name and date in the box provided.

   The terms and conditions of this grant may be modified or amended by AACR prior to execution of the Grant Agreement. In addition, the grant recipient’s institution may only request revisions to sections VII.F.; XII.; XIII.F.; IX. (to be negotiated with Novocure); and XIV.A. of the Grant Agreement prior to execution. Only in special circumstances will revisions be considered to sections other than those noted above.

2. DOWNLOAD TEMPLATES & INSTRUCTIONS. The Program Guidelines and Application Instructions document, the Materials Transfer Agreement Statement, and all templates can be downloaded from this page. Applicants are required to use the application template.

   See Section 10 of the Application Instructions for how to complete and upload the templates. This application also requires additional attachments for which templates are not provided (applicant’s biographical sketch, Letter of Institutional Commitment, Materials Transfer Agreement [if applicable],
biographical sketch(es) of collaborator(s) [if applicable], Letter(s) of Collaboration [if applicable], Supporting Documentation [if applicable], and Appendices [if applicable]).

3. ENABLE OTHER USERS TO ACCESS THIS PROPOSAL. Optional.

4. APPLICANT. Enter information for the applicant. Applicants must include their contact information, including e-mail address, phone number, and mailing address.

Applicants who have an ORCID ID are also invited to include this identifier with their application.

5. INSTITUTION & CONTACTS. Enter information regarding the applicant’s institution and signing official.

6. COLLABORATORS. Collaborators are optional. Collaborators are independent researchers who have an integral role on the proposed project. Do not enter information for fellows or research assistants working on the proposed project as they are not considered collaborators. While collaborators are allowable, note that co-Principal Investigators are NOT permitted.

7. SCIENTIFIC ABSTRACT. The abstract is limited to 3,000 characters (including spaces) and should provide a brief summary of the proposed research project.

If funded, this Abstract may become public information; therefore, do not include proprietary/confidential information.

From the lists provided, select the research areas that are most applicable to this project (select no more than two), select the tumor site that is most applicable to this project (select only one), and indicate how you found out about this grant opportunity.

8. BUDGET. Applicants must submit a budget in the amount of $250,000 total over a two-year grant term. Enter proposed expenses related to the research project, which may include the salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs associated with graduate students’ education and training), and research assistants, or collaborators; research/laboratory supplies; equipment, publication charges for manuscripts that pertain directly to the funded project; and other research expenses. The percentage of salary requested may not exceed the percent effort of the applicant. See Grant Agreement document for information on publishing in AACR journals. No more than 25% of the total budget can be allocated to grant recipient and collaborator salary and benefits. No grant funds may be directed to collaborators or consultants working within U.S. government entities or for-profit private industry. Budget requests for equipment that exceed 10% of the total budget must be accompanied by a detailed justification.

Up to $3,000 per year may be used for registration, housing, travel, and subsistence expenses related to attendance at any scientific meetings or conferences applicable to the research project. Grantee must attend the AACR Annual Meeting 2020 to formally accept the grant during the annual Grants Reception and Dinner. Travel funds are for the grantee ONLY. Up to $2,500 may be allocated from the grant to support the grantee’s registration and attendance at any individual meeting or conference.
For institutions that mandate payment of indirect costs, a maximum of 10% of the total direct costs may be used for this purpose.

As the grant term begins after the Annual Meeting to which the grantee must attend, the AACR recommends that the Institution using existing discretionary funding to cover the grantee’s travel costs. When the grant term begins, the Institution may transfer the applicable AACR-allowed travel charges from the discretionary fund to the grant fund. This transfer must be reflected in the first financial report of expenditures submitted to the AACR.

Professional membership dues and any other expenses not directly related to the project are not allowable expenses. In addition, no grant funds may be directed towards salary or benefits of any individuals from a U.S. government entity or for-profit industry, nor for any research expenses related to the project that are incurred by these individuals.

A detailed budget justification explaining the allocation of the grant funds must accompany the application. See Section 10.D. for Budget Justification template instructions.

9. ORGANIZATIONAL ASSURANCES. Select the appropriate assurances options for your proposed research and complete the Approved or Pending Date field as appropriate (i.e., mm/dd/yyyy, N/A, or None). The assurances/certifications are made and verified by the signature of the institutional official signing the application. If a grant is awarded, IRB and/or IACUC approval (if applicable) must be submitted in writing to the AACR’s SRGA.

10. APPLICATION DOCUMENTS.
   Formatting Instructions. Applicants must adhere to the following instructions in completing the templates. Failure to observe type size specifications and page limits will result in the return of the application without review.

   • **Type size.** Must use 12-point Times New Roman for the text, and no smaller than 9-point type for figures, legends, and tables.
   • **Single-spaced text.** Single-spacing is acceptable, and space between paragraphs is recommended.
   • **Margins.** The page margins must be no less than 0.75 inches on each side.
   • **Page numbering.** The Proposal Narrative must be numbered consecutively; do not use section designations such as "3A" or "3B".
   • **Tips and techniques for inserting images in documents.**
     o Reduce the file size of documents with images by “inserting” the image (as opposed to “cutting” and “pasting”). Save graphical images as JPG or GIF files. Insert the image into the document by selecting “Insert – Picture – From File” from the MS Word menu.
     o Insert only GIF or JPG graphic files as images in your Word document. Other graphical file formats are either very large or difficult to manipulate in the document.
     o Do not insert Quick Time or TIFF objects into your document.
     o Anchor the images that you embed in your document.
     o Once you have anchored the inserted image, you can format text to wrap around the image.
     o Do not edit your images in Word. Use a graphics program.
     o Do not embed your images in tables, text boxes, and other form elements.
When a template is provided, the template MUST be used. Prepare and upload the following documents into your application in portable document format (PDF):

A. **Research Project Proposal.** Applicants are required to use the template available from the proposalCENTRAL website. The information must be presented in this order:

   I. **Contents Page.** Complete the Table of Contents by indicating the appropriate page numbers for each section. The Table of Contents page must not exceed one page.

   II. **Proposal Narrative.** Limited to six pages, including figures and tables. The Contents Page, Facilities, and References sections do not count against this page limit. The Proposal Narrative must be presented in this order and should include these subheadings: (A) Title of Research Project; (B) Introductory Statement, Background, Preliminary Data, and Rationale; (C) Specific Aims; (D) Research Design and Methods*; (E) Statement of Innovation (describing how the proposed study employs a new idea and/or innovative approach); and (F) Significance and Statement of Relevance.

      *Note that AACR strongly encourages the authentication of cell lines intended for use in the proposed research project. If use of cell lines is proposed, it is encouraged that information related to cell line authentication is included in the Research Design and Methods section of the proposal. For a list of cell line authentication services, please visit: [http://aacrjournals.org/content/cell-line-authentication-information](http://aacrjournals.org/content/cell-line-authentication-information)

   III. **Facilities.** Limited to two pages. Please provide a description of the research facilities, resources, and equipment that are available to the applicant and that will allow successful implementation of the proposed research program.

   IV. **References.** Limited to three pages. AACR reference style follows that of the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals*. Note that the Uniform Requirements specify that for articles with more than six authors, the names of the first six authors must be listed, followed by "et al." For articles with six or fewer authors, all authors should be listed.

B. **Secured Other Support.** Applicants are required to use the template available from the proposalCENTRAL website. In the table provided, list all existing support (institutional, federal, etc.) that has been secured and will be used in whole or in part by the applicant during the term of this grant (07/01/2020-06/30/2022). Only funding sources that provide support specifically for the applicant should be listed, which includes grants for which the applicant is not the Principal Investigator. This may include support for different projects. For each grant or funding source, please provide:

   - Name of Principal Investigator
   - Name of Grant/Funding Source
   - Funding Agency
   - Grant Term
C. **Pending Other Support.** Applicants are required to use the template available from the proposalCENTRAL website. In the table provided, list all pending support (institutional, federal, etc.) that will, if secured, be used in whole or in part by the applicant during the term of this grant (07/01/2020-06/30/2022). Only funding sources that provide support specifically for the applicant should be listed, which includes grants for which the applicant is not the Principal Investigator. This may include different projects. For each pending grant or funding source, please provide:

- Name of Principal Investigator
- Name of Grant/Funding Source
- Funding Agency
- Grant Term
- Amount of Funding
- Percent Effort of Applicant
- Title of Project
- List of Specific Aims as Stated in Grant Proposal (summaries will NOT be accepted)

**NOTE:** If at any time prior to selection and notification an applicant is awarded any funding that may overlap with the 2020 AACR-Novocure Tumor Treating Fields Research Grants, the applicant must notify the AACR immediately.

D. **Budget Justification.** Applicants are required to use the template available from the proposalCENTRAL website. Limited to three pages. Applicants must submit a budget in the amount of $250,000 over two years. Percent effort of the applicant on the proposed project must be indicated. Applicant must also indicate their salary and, if any part of their salary is requested, the percentage of salary requested may not exceed the percent effort the applicant will dedicate to the project. In addition, identify by name and title of any additional personnel, including collaborators, and their specific responsibilities, during each year of the proposed project. Note if individual is a postdoctoral or clinical research fellow. For positions that are not yet filled, indicate “TBD” in the name field. **Grant recipient and collaborator(s) salary and benefits are limited to 25% of the total budget.** Include details on any research/laboratory supplies, equipment, travel, publication charges for manuscripts that pertain directly to the funded project, and other research expenses being requested. Detailed justification is required for equipment that exceeds 10% of the total budget.

Travel expenditures cannot exceed $3,000 per year. Travel funds are for the grantee ONLY. No more than $2,500 may be allocated to support registration and attendance at any individual meeting or conference.

E. **Project Milestones.** Complete only Column A of the Milestones Template available from the proposalCENTRAL website. The Milestones Template is meant to list the various steps necessary
to complete your research goals and the estimated time it will take to complete each step. Please list your name and the specific aims for the proposed project at the top of the template. Underneath each time period, identify the steps that will be needed to accomplish the aim(s) in that time period. For each step, note the corresponding aim in parentheses. Rows may be added/deleted to the template as needed. **For the purposes of submitting the template with your application, only the information requested above entered into Column A is needed.** Reporting progress towards milestones further using this template will be incorporated into the reporting requirements for the project if funded.

F. **Applicant’s Biographical Sketch.** The biographical sketch must be in English. The NIH Biographical Sketch Form [OMB No. 0925-0001 and 0925-0002 (Rev. 9/17 Approved Through 3/31/2020)] should be used.

G. **Letter of Institutional Commitment.** The letter must be written by the department head, dean, or other senior member of the institution on behalf of the applicant and addressed to the Scientific Review Committee. It should explain the applicant’s relationship with the institution, and the nature and extent of support for the proposed research available from the institution, including laboratory space and financial and other resources.

H. **Biographical Sketch(es) of Collaborator(s).** Submit a biographical sketch for every collaborator listed in Section 6. The biographical sketch must be in English. The NIH Biographical Sketch Form [OMB No. 0925-0001 and 0925-0002 (Rev. 9/17 Approved Through 3/31/2020)] should be used.

I. **Letter(s) of Collaboration.** A Letter of Collaboration must be uploaded for every collaborator listed in Section 6. The letter should confirm the scope of the collaborators’ involvement in the proposed research.

J. **Supporting Documentation.** An example of acceptable supporting documentation is a letter of commitment from a collaborating clinician, drug manufacturer, or any collaborator providing data or materials necessary for the proposed research. Supporting Documentation should state a commitment to provide stated data/materials or confirm applicant’s access to said data/materials. Supporting Documentation should be included only to provide information on the ability to provide for a research need, and should not comment on the applicant, or research environment. **Any documentation deemed by the AACR’s SRGA to be a letter of reference for the applicant is not considered supporting documentation and will be removed from the application.** Each supporting document is limited to one page and must be presented on the appropriate institutional or company letterhead.

There is no limit to the number of supporting documents that may be provided, however, documents that do not satisfactorily meet the description of supporting documentation provided above, or uploads such as tables, charts, articles, and other inappropriate additional materials will be removed.

K. **Appendices.** Appendices are not required and may ONLY be used for the following materials. Appendices are not to include figures, tables, or other data that otherwise should be contained within the Proposal Narrative. The following materials are permitted:
- Clinical Trial Protocols
- Unpublished Manuscripts. (Manuscripts that have been published should not be attached as appendices. Instead, please list the citation on the References page.)
- Large size versions of figures and/or detailed legends presented in the Proposal Narrative. The use of this appendix is in no way intended to increase the Proposal Narrative page limit. Use of this appendix is restricted to no more is restricted to no more than one page of figures and/or legends. This appendix is to be used when reducing the size of the figure or legend to fit within the proposal narrative would significantly compromise the quality of the image. In no case should there be more than one page of text in this appendix. **Overuse or misuse of this appendix may result in your application being rejected or your appendix being removed from your application.**

L. **Materials Transfer Agreement Statement/Materials Transfer Agreement.** For applicants from institutions that do not currently hold a Materials Transfer Agreement with Novocure: in order to ensure that the applicant is informed of the Materials Transfer Agreement terms of the grant should they be selected as a recipient, a copy of the Materials Transfer Agreement Statement must be downloaded from the proposalCENTRAL site. **Applicants and the institution’s designated Technology Transfer Office official must sign and date the Statement, indicating that they are aware of the requirement of executing a timely Materials Transfer Agreement between the Institution with Novocure before confirmation of the grant should they be selected.** For applicants from Institutions that hold a fully executed Materials Transfer Agreement with Novocure: the provision of the existing Materials Transfer Agreement between the institution and Novocure shall apply to the proposed project to be performed pursuant to the grant and the provisions of the Materials Transfer Agreement shall be amended or supplemented for such purpose, to the extent required by Novocure. **The fully executed Materials Transfer Agreement should be uploaded.** Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures.

If applicable, the AACR will facilitate contact between the institution and Novocure so they may directly conduct negotiations regarding the terms and conditions of the Materials Transfer Agreement. Institution will use good faith efforts to expedite negotiation and execution of the Materials Transfer Agreement to enable timely confirmation of the grant and commencement of the grant.

In addition, collaborators (if applicable) will be required to confirm in writing that they are subject to all applicable provisions and obligations applicable to the applicant under the Materials Transfer Agreement between the institution and Novocure.

**The signed Materials Transfer Agreement Statement/Materials Transfer Agreement must be uploaded to your online application in the Application Documents section.**

M. **Signed Signature Page.** In order to ensure that the applicant and institution have approved the application, applicants must obtain both required signatures on page one of the Signature Pages. Electronic/digital signatures are permitted. These signatures transmitted by electronic means shall have the same force and effect as original signatures. Downloading the Signature Page(s) is described in Section 13 below.
The **signed Signature Page** must be uploaded to your online application in the Application Documents section.

**Uploading the attachments into your application.** Once you have converted your attachments to PDF files, the next step is to upload the files to your online application. *Only PDF attachments are permitted for this application submission.*

- Open your online application and go to the section for attaching files. Click the blue “Attach Files” button.
- Select the appropriate type of attachment from the drop-down list.
- Enter your own description of the file in the “Describe Attachment” field.
- Click on the “Browse” button to select the file from your computer.
- Click on the “Upload and Continue” button. You will get a confirmation message on your screen that the file was uploaded successfully. You will also see that your file is now listed in the “Uploaded Attachment” section of the screen. Clicking the “Back” or “Upload and Return” button allows you to go back to the main page of this section where the uploaded documents should now be listed. **Click the download icon next to the file name to open and view your uploaded documents.** To delete the file, click on the trashcan icon to the right under the “Delete” column.

In this section for attachments, all the required attachments are listed in the middle of the screen, just below where you upload your files. This list of required attachments helps you track completion and uploading of your required attachments. Once you upload a required attachment, that attachment type will be removed from the required list and will be displayed in the “Current list of uploaded attachments”.

If you wish to modify the attached file, make the revisions to your original file on your computer, convert the file to PDF, and use the same process as above to attach the new file. **Delete any previously submitted versions of the file before submitting your application.**

**SUBMITTING COMPLETE APPLICATION**

11. **PI DATA SHEET.** This is an automatically populated data sheet based on the applicant’s proposalCENTRAL profile. Information for gender, race, and ethnicity must be provided to the AACR. If fields are not populated, go to Section 4, “Applicant”, and select the “Edit Professional Profile” button in the center of the screen. The applicant must then go to the column on the left side of the screen, select “4) Personal Data for Application”, and enter their gender, race, and ethnicity. The Scientific Review Committee does not receive this information.

12. **VALIDATE.** Validate the application on proposalCENTRAL. This is an essential step. An application that has not been validated cannot be submitted. “Validate” checks for required data and attachments. You will not be able to submit if all the required data and attachments have not been provided.

13. **SIGNATURE PAGE(S).** Use the “Print Signature Pages” button to download the Signature Pages. Signatures are only required on the first page. This page can be printed, original signatures obtained, and then uploaded to your online application OR electronic/digital signatures are permitted. These
signatures transmitted by electronic means shall have the same force and effect as original signatures. Do not upload the Application Contacts, Scientific Abstract, and Proposed Budget pages with the signed Signature Page.

**NOTE:** Data entered in the online application are automatically included in the Signature Pages. If information is missing in the Signature Pages, it could be because you have not entered the information in one of the online application sections OR the information is not required for this grant program. If the institution’s Employer Identification Number (EIN) is not completed on the Signature Page, please request that your institution provides that information in their proposalCENTRAL profile.

While the “Print Signature Pages” option allows applicants to download the Signature Page, Application Contacts, Scientific Abstract, and Budget, the AACR **strongly encourages** applicants to also use the “Print Signature Pages with Attachments” option. This option can be used if your institution wishes to review the full application but also should be used by the applicant to ensure that your attachments loaded properly. The following application materials will **not** be present when using this option: Pending Other Support, Materials Transfer Agreement Statement Signature Page/Materials Transfer Agreement, and the Signature Page containing the required signatures. Absence of these materials should **not** be considered an error. If your institution requires all components of the application to review, the above documents need to be added individually by the applicant.

Excessive spacing in your Scientific Abstract (e.g., line breaks between paragraphs) can cause the abstract to not fully appear in the Signature Page view, even if under the 3,000 character limit. You may want to further edit your Scientific Abstract prior to submission if it does not fully appear. Errors may occur when the uploaded PDF files are assembled by the system. Please check to ensure that all pages of every document included appear in the “Print Signature Pages with Attachments” option. If you are having any issues with this option, please contact proposalCENTRAL customer support at: 800-875-2562 (Toll-free U.S. and Canada), +1-703-964-5840 (Direct Dial International), or by e-mail to pcsupport@altum.com.

**14. SUBMIT.** After successfully passing the validate check, click the **“Submit”** link. An e-mail will be sent to you confirming your submission.

Once your application is submitted you may view it by selecting “Submitted” from the “Proposal Status” drop-down menu under the ‘Proposals’ tab, then clicking the “View” button under the Edit column. The status column will show “Submitted” and the date submitted. You may need to refresh your browser screen after submitting the application to see the updated status.

**CHANGES TO YOUR APPLICATION**

**Withdrawal of Application.** Please advise the AACR’s SRGA promptly, in writing, should you decide to withdraw your application for any reason. Your correspondence should include your name, the grant opportunity to which you applied, the project title, and the reason for withdrawal.

**Change of Address.** Notify the AACR in writing of any changes of address, e-mail, or phone number, following the submission of an application. Include your name and the proposalCENTRAL identification
number. The e-mail address provided with your application will be used for all official communication about your submission including the recipient selection results. Your Professional Profile in proposalCENTRAL must be kept up to date.

**Change of Institution or Position.** If you change your institution or professional position, contact the AACR’s SRGA to determine whether your application is still eligible for review.

**INQUIRIES**
Inquiries or technical issues regarding proposalCENTRAL and the online application process should be directed to customer support at 800-875-2562 (Toll-free U.S. and Canada), +1-703-964-5840 (Direct Dial International), or by e-mail at pcsupport@altum.com.

Inquiries about the program guidelines, eligibility requirements, and application materials can be directed to the AACR’s Scientific Review and Grants Administration at grants@aacr.org.
### TABLE 1: INSTITUTIONS THAT HOLD A MATERIALS TRANSFER AGREEMENT WITH NOVOCURE

<table>
<thead>
<tr>
<th></th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Beth Israel Deaconess Medical Center, MA, USA</td>
</tr>
<tr>
<td>2</td>
<td>UT Southwestern Medical Center, TX, USA</td>
</tr>
<tr>
<td>3</td>
<td>Stanford University, CA, USA</td>
</tr>
<tr>
<td>4</td>
<td>University Hospital Zurich, Switzerland</td>
</tr>
<tr>
<td>5</td>
<td>Sourasky Medical Center, Tel-Aviv, Israel</td>
</tr>
<tr>
<td>6</td>
<td>Universitätsklinikum Würzburg, Germany</td>
</tr>
<tr>
<td>7</td>
<td>University Clinic Hamburg-Eppendorf, Germany</td>
</tr>
<tr>
<td>8</td>
<td>Wayne State University School of Medicine, MI, USA</td>
</tr>
<tr>
<td>9</td>
<td>University of Nottingham, UK</td>
</tr>
<tr>
<td>10</td>
<td>Korea Institute of Radiological and Medical Sciences, Seoul, Korea</td>
</tr>
<tr>
<td>11</td>
<td>Palacký University Olomouc, Czech Republic</td>
</tr>
<tr>
<td>12</td>
<td>University of Florida, FL, USA</td>
</tr>
<tr>
<td>13</td>
<td>Spanish National Cancer Centre (CNIO), Spain</td>
</tr>
<tr>
<td>14</td>
<td>Netherlands Cancer Institute (NKI), Netherlands</td>
</tr>
<tr>
<td>15</td>
<td>University of Sheffield, UK</td>
</tr>
<tr>
<td>16</td>
<td>Tulane University School of Medicine, LA, USA</td>
</tr>
<tr>
<td>17</td>
<td>Heinrich-Heine University Düsseldorf, Germany</td>
</tr>
<tr>
<td>18</td>
<td>University Clinics for Neurosurgery, Bern, Switzerland</td>
</tr>
<tr>
<td>19</td>
<td>Neurocenter of Southern Switzerland</td>
</tr>
<tr>
<td>20</td>
<td>University of Milano, Milano, Italy</td>
</tr>
<tr>
<td>21</td>
<td>University Heidelberg, Germany</td>
</tr>
<tr>
<td>22</td>
<td>University of Minnesota, MN, USA</td>
</tr>
<tr>
<td>23</td>
<td>Goethe University Hospital, Germany</td>
</tr>
<tr>
<td>24</td>
<td>Cancer Research Center (DKFZ), Heidelberg, Germany</td>
</tr>
<tr>
<td>25</td>
<td>New York University School of Medicine, NY, United States</td>
</tr>
<tr>
<td>26</td>
<td>Jena University Hospital – Friedrich Schiller University Jena, Germany</td>
</tr>
<tr>
<td>27</td>
<td>Western University of Health Sciences, Pomona, CA, USA</td>
</tr>
<tr>
<td>28</td>
<td>Istituto di Recerche Farmacologiche Mario Negri IRCCS, Milano, Italy</td>
</tr>
<tr>
<td>29</td>
<td>Justus-Liebig University Giessen, Germany</td>
</tr>
</tbody>
</table>
MORE ABOUT THE PARTNERS

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit [www.novocure.com](http://www.novocure.com) or follow us at [www.twitter.com/novocure](http://www.twitter.com/novocure).

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR has 42,000 members in 120 countries and territories around the world; over thirty percent (30%) of members live outside the United States and Canada. Twenty percent (20%) of AACR’s international members are located in countries with emerging economies. The AACR offers seven categories of membership to support each aspect of our members' professional development and enhancement in cancer research. In support of the professional development of early-career investigators, no annual dues are required for Associate membership. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 22,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit [www.AACR.org](http://www.AACR.org).